Journal
JOURNAL OF HEMATOLOGY & ONCOLOGY
Volume 8, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s13045-015-0122-8
Keywords
Anaplastic lymphoma kinase; ALK-1; Crizotinib; Ceritinib
Categories
Funding
- Henan Tumor Hospital, Zhengzhou University, Zhengzhou China
Ask authors/readers for more resources
Anaplastic lymphoma kinase 1 (ALK-1) is a member of the insulin receptor tyrosine kinase family. ALK-1 was initially found in anaplastic large cell lymphoma (ALCL). ALK mutations have also been implicated in the pathogenesis of non-small cell lung cancer (NSCLC) and other solid tumors. Multiple small molecule inhibitors with activity against ALK and related oncoproteins are under clinical development. Two of them, crizotinib and ceritinib, have been approved by FDA for treatment of locally advanced and metastatic NSCLC. More agents (alectinib, ASP3026, X396) with improved safety, selectivity, and potency are in the pipeline. Dual inhibitors targeting ALK and EGFRm (AP26113), TRK (TSR011), FAK (CEP-37440), or ROS1 (RXDX-101, PF-06463922) are under active clinical development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available